.2

LinkedIn Post by Rohan Palekar, Chief Executive Officer of 89bio, on September 18, 2025

Today is a proud moment for 89bio and the amazing team who has worked on pegozafermin. Since our inception in May 2018, this extraordinary group of individuals were driven by a mission to help patients with severe liver and cardiometabolic disease. Over these years, we experienced the many highs and lows that small biotech companies go through. I was aware that drug development and manufacturing scale-up is not easy, but what this team showed me is that a resilient team with a passion for their beliefs and mission, can overcome all challenges. I am incredibly proud to have had the chance to work with everyone who has touched 89bio.

Our acquisition by Roche announced this morning is the next phase in the journey to bring pegozafermin to help patients. I believe that Roche with its commitment to cardiovascular, renal and metabolic diseases, is the ideal company to accelerate the program and bring pegozafermin to patients suffering from MASH and SHTG globally.

I am grateful for the support we received from multiple stakeholders through our journey – our advisors, vendors, experts, investors, the board and many others. And above all, the investigators and the trial participants who have been part of our trials. Along the way, there were many friendships built and I will always cherish those. Now we continue our work to move the program forward.

“Today we entered into a merger agreement to be acquired by @Roche. At the closing of the proposed transaction, 89bio and its employees will join the Roche Group and advance our innovative FGF21 analog, pegozafermin, as part of Roche’s Pharmaceuticals Division. Details here: https://ir.89bio.com/news-releases/news-release-details/89bio-inc-announces-agreement-be-acquired-roche ”